REPLIMUNE GROUP, INC. (REPL) Current Ratio
- Current ratio · latest quarter: Value 5.23×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.23× | Current assets / current liabilities. $200.81M ÷ $38.41M ≈ 5.23× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 200.81M USD | Assets, Current |
| Current obligations | 38.41M USD | Liabilities, Current |
| Cash and equivalents | 185.36M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 4.26M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $200.81M | $38.41M | $185.36M | (m) | (m) | (m) | $4.26M | (m) | 5.23× |
| 2026-03-31 | $279.12M | $58.23M | $209.02M | (m) | (m) | (m) | $6.67M | (m) | 4.79× |
| 2025-12-31 | $280.35M | $50.09M | $122.95M | (m) | (m) | (m) | $5.65M | (m) | 5.60× |
| 2025-09-30 | $333.75M | $52.90M | $102.30M | (m) | (m) | (m) | $6.40M | (m) | 6.31× |
| 2025-06-30 | $413.37M | $59.56M | $97.37M | (m) | (m) | (m) | $15.48M | (m) | 6.94× |
| 2025-03-31 | $495.88M | $62.36M | $111.12M | (m) | (m) | (m) | $12.46M | (m) | 7.95× |
| 2024-12-31 | $547.58M | $47.89M | $172.25M | (m) | (m) | (m) | $7.19M | (m) | 11.43× |
| 2024-09-30 | $442.63M | $43.79M | $113.49M | (m) | (m) | (m) | $8.41M | (m) | 10.11× |
| 2024-06-30 | $480.32M | $35.68M | $151.66M | (m) | (m) | (m) | $864.00K | (m) | 13.46× |
| 2024-03-31 | $433.67M | $40.44M | $74.46M | (m) | (m) | (m) | $2.58M | (m) | 10.72× |
| 2023-12-31 | $479.16M | $38.65M | $97.67M | (m) | (m) | (m) | $3.90M | (m) | 12.40× |
| 2023-09-30 | $508.18M | $39.83M | $76.00M | (m) | (m) | (m) | $4.37M | (m) | 12.76× |
| 2023-06-30 | $550.04M | $32.24M | $106.48M | (m) | (m) | (m) | $4.88M | (m) | 17.06× |
| 2023-03-31 | $592.60M | $33.83M | $146.59M | (m) | (m) | (m) | $5.36M | (m) | 17.52× |
| 2022-12-31 | $623.96M | $26.46M | $206.67M | (m) | (m) | (m) | $3.65M | (m) | 23.58× |
| 2022-09-30 | $379.39M | $23.54M | $88.93M | (m) | (m) | (m) | $4.00M | (m) | 16.12× |
| 2022-06-30 | $401.95M | $20.31M | $112.25M | (m) | (m) | (m) | $4.48M | (m) | 19.79× |
| 2022-03-31 | $403.98M | $20.76M | $105.95M | (m) | (m) | (m) | $3.73M | (m) | 19.46× |
| 2021-12-31 | $427.80M | $18.29M | $132.28M | (m) | (m) | (m) | $3.92M | (m) | 23.39× |
| 2021-09-30 | $444.38M | $16.64M | $159.97M | (m) | (m) | (m) | $3.15M | (m) | 26.71× |
| 2021-06-30 | $464.56M | $15.05M | $192.53M | (m) | (m) | (m) | $2.38M | (m) | 30.87× |
| 2021-03-31 | $483.75M | $14.55M | $182.52M | (m) | (m) | (m) | $2.35M | (m) | 33.25× |
| 2020-12-31 | $499.43M | $13.02M | $324.48M | (m) | (m) | (m) | $2.35M | (m) | 38.36× |
| 2020-09-30 | $252.41M | $12.96M | $43.33M | (m) | (m) | (m) | $2.37M | (m) | 19.47× |
| 2020-06-30 | $267.74M | $11.88M | $104.80M | (m) | (m) | (m) | $3.48M | (m) | 22.54× |
| 2020-03-31 | $174.25M | $11.87M | $59.50M | (m) | (m) | (m) | $3.43M | (m) | 14.68× |
| 2019-12-31 | $190.87M | $14.22M | $63.00M | (m) | (m) | (m) | $6.26M | (m) | 13.43× |
| 2019-09-30 | $118.01M | $11.98M | $53.30M | (m) | (m) | (m) | $7.96M | (m) | 9.85× |
| 2019-06-30 | $127.74M | $13.05M | $38.36M | (m) | (m) | (m) | $10.83M | (m) | 9.79× |
| 2019-03-31 | $140.98M | $9.88M | $25.70M | (m) | (m) | (m) | $7.08M | (m) | 14.26× |
| 2018-12-31 | $144.95M | $3.81M | $21.05M | (m) | (m) | (m) | $1.50M | (m) | 38.06× |
| 2018-09-30 | $151.87M | $3.74M | $23.28M | (m) | (m) | (m) | $2.07M | (m) | 40.56× |
| 2018-06-30 | $55.22M | $4.50M | $12.91M | (m) | (m) | (m) | $2.85M | (m) | 12.28× |
| 2018-03-31 | $64.70M | $5.16M | $17.58M | (m) | (m) | (m) | $1.99M | (m) | 12.53× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B |